IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Study Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor the KRAS G12C mutation. Treatment Regimen: All enrolled subjects will receive IBI351 combined with cetuximab β injection. Treatment will continue until disease progression (as assessed by the investigator per RECIST 1.1 criteria) or the occurrence of intolerable toxicity. Primary Endpoint: Objective Response Rate (ORR) as assessed by the investigator according to Resp

Trial Details

NCT ID
NCT07198841
Phase
PHASE2
Sponsor
Guangdong Association of Clinical Trials
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • IBI351 combined with cetuximab β
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Beijing, China|39.9075,116.39723
  • Foshan, China|23.02677,113.13148
  • Nanchang, China|28.68396,115.85306
  • Nanchang, China|28.68396,115.85306

Key Eligibility Criteria

  • Voluntarily participate in the study and sign the informed consent form (ICF).
  • Male or female subjects aged ≥18 years and ≤75 years at the time of signing the ICF.
  • Life expectancy ≥ 3 months.
  • Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) non-small cell lung …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →